Opinion
Breast cancer in the family – genetic insights from the Arab population
When a breast cancer diagnosis is made, it often raises questions about hereditary risk. Dr Julie Decock explores how new QBRI research is helping to answer these questions for Arab populations
October marks Breast Cancer Awareness Month, when attention turns to the importance of early detection, prevention, and advances in treatment and care. Understanding breast cancer risk includes awareness of lifestyle factors that are within an individual’s control, such as physical activity, diet and alcohol consumption, and those that we cannot alter, including gender, age and genetic blueprint.
Most breast cancers are not caused by a single genetic change. However, when several members of a family develop breast cancer, especially at a younger age, this may indicate an inherited susceptibility to the disease. Advancing our understanding of this predisposition is becoming increasingly important as medicine moves towards more personalised approaches to assess risk, prevent disease and select treatments. Yet, an important question remains: how well do we understand these risks when some populations remain underrepresented in genetic research?
Hereditary Breast Cancer
Hereditary breast cancer occurs because of inherited changes in genes that increase cancer risk, known as cancer susceptibility genes. These genetic changes are called germline gene variants because they are present in all cells in the body from conception and can be passed from one generation to the next.
The best-known genes associated with hereditary breast cancer are BRCA1 and BRCA2, which play important roles in repairing damaged DNA. Harmful variants in these genes can substantially increase the risk of breast and ovarian cancer. Individuals who inherit harmful BRCA1 and BRCA2 alterations have a lifetime breast cancer risk of approximately 70%, although the actual risk varies between individuals. Identifying such variants can therefore have important implications not only for the treatment and overall clinical care of a patient, but also for relatives who may carry the same gene variant. However, not all hereditary breast tumours can be linked back to harmful BRCA1/2 gene alterations. Current guidelines from the National Comprehensive Cancer Network (NCCN) define specific inherited variants in the CDH1, PALB2, PTEN, STK11, and TP53 genes to be associated with a significantly higher risk of breast cancer, while variants in several other genes are defined to be associated with more moderate increases in risk.
Genetic risk can also arise from the combined effects of many common genetic variants, which individually might have only minor impact. Polygenic risk scores (PRS) combine information from hundreds or even millions of these variants to estimate a person’s inherited predisposition to breast cancer. Importantly, genetic variants that are common in one population may be less common in another, and their contribution to disease risk may also differ per population.
As such, risk estimates developed using predominantly Caucasian populations may not accurately reflect risk in other populations. Expanding genetic research to include diverse populations is therefore important for developing risk assessment approaches that are relevant for different populations.
Population-Specific Insights from a Qatar-Led Study
Research led by the Qatar Biomedical Research Institute (QBRI), part of Hamad Bin Khalifa University (HBKU), is providing new insights into hereditary breast cancer in Arab populations. In collaboration with the King Hussein Cancer Center in Jordan and researchers from the Qatar Computing Research Center (QCRI), also part of HBKU, the work addresses a knowledge gap in the genetic landscape of hereditary breast cancer.
Emerging studies from the Middle East and North Africa (Mena) region have demonstrated why population-specific genetic research is critical. Differences in the frequency and distribution of genetic variants have been observed among Arab populations. Previous research from Qatar highlighted differences in the distribution of cancer-predisposing variants across population groups, including individuals of Persian and Arabian Peninsula origins. In Saudi Arabia, breast cancer patients who did not carry harmful BRCA1/2 variants were found to have harmful variants in the moderate-risk ATM gene. These findings illustrate that Caucasian-focused studies may limit our understanding of genetic factors that may contribute to enhanced cancer risk in Arab populations.
In a recent study by HBKU scientists, published in npj Breast Cancer, researchers studied the presence of genetic variants in 180 Arab patients from Jordan with high-risk familial breast cancer who tested negative for harmful BRCA1/BRCA2 variants. Comparative genetic analysis of approximately 6,000 healthy Arab women, participating in the Qatar Precision Health Institute biorepository programme, identified several harmful variants in the high-risk genes PALB2 and TP53, and in the moderate-risk genes ATM and BARD1 in patients, but not in healthy women. Notably, they also found a variant in the high-risk TP53 gene, as well as variants in the cancer-related PASK and CHEK1 genes. While TP53 is an established breast cancer risk gene, the biological and clinical significance of the specific variants identified in these genes remains unclear and requires further study.
These findings support the possibility that inherited changes in genes other than BRCA1 and BRCA2 contribute to hereditary breast cancer in Arab populations. However, whether these variants represent population-specific risk factors remains unknown. The need for population-specific research is further highlighted by the analysis of 120 existing breast cancer polygenic risk scores, largely developed using populations of European ancestry, with fewer than half distinguishing patients from healthy individuals in the study cohort. Ongoing work aims to extend these findings to other Arab populations, including the Qatari population in collaboration with Hamad Medical Corporation (HMC).
From Population Genomics to Precision Medicine
The QBRI-led study on hereditary breast cancer is part of a broader effort to understand the biological and genetic factors that contribute to breast cancer in Arab populations. Precision medicine goes beyond identifying a single genetic risk factor. It involves understanding why cancer develops and advances, and why patients can respond differently to the same treatment.
This may include identifying individuals and families who could benefit from closer surveillance, developing biomarkers to predict treatment response, discovering new therapeutic targets, and selecting treatments based on the characteristics of an individual’s tumour. By combining research across different levels - from population genomics to the molecular and functional characterisation of individual tumours – QBRI researchers aim to contribute to a more comprehensive and locally relevant approach to precision medicine. Together, these efforts can help advance breast cancer care that is better informed by the biological and genetic diversity of populations across the region.
- Dr Julie Decock is a Senior Scientist at Hamad Bin Khalifa University’s Qatar Biomedical Research Institute.
About Hamad Bin Khalifa University
Innovating Today, Shaping Tomorrow.
Hamad Bin Khalifa University (HBKU), a member of Qatar Foundation for Education, Science, and Community Development (QF), is a leading, innovation-centric university committed to advancing education and research to address critical challenges facing Qatar and beyond. HBKU develops multidisciplinary academic programs and national research capabilities that drive collaboration with leading global institutions. The university is dedicated to equipping future leaders with an entrepreneurial mindset and advancing innovative solutions that create a positive global impact.
For more information about HBKU, its colleges, research institutes, and initiatives, please visit www.hbku.edu.qa
To stay up to date on our social media activities, follow our accounts on: LinkedIn, Instagram, X, and Facebook.
For any media inquiries, please contact: media@hbku.edu.qa.